Imugene’s $20 million boost and cancer trial updates

(7:42)

Imugene: A worldwide license to attack blood cancer

(2:59)

Imugene’s $20 million boost and cancer trial updates

(7:42)

Imugene MAST trial delivers two-year complete response in bile tract cancer patient

(4:54)

Imugene (ASX:IMU) | Webinar with Leslie Chong | 07/11/24

(26:56)

Imugene begins VAXINIA trial for bile tract cancer

(10:)

Developing Cancer Cures through the ASX | Going Public w Leslie Chong \u0026 Paul Hopper

(53:26)

Groundbreaking cancer trial: Imugene’s CF33 advances in clinical success

(16:2)

Imugene (ASX:IMU) | JMM \u0026 éthica Capital Innovation \u0026 Investment Insights | May 2024

(15:6)

Cramer: This biotech stock could be worth over $100 billion on an FDA approval

(5:19)

Interview With The CF33 Oncolytic Virus Inventor - Imugene (IMU)

(20:11)

A Californian Cancer Killer Professor Yuman Fong and his work with Imugene

(26:16)

Imugene's Science Series: PD1-Vaxx | B cell immunotherapy

(32:59)

Investor webinar: Azer-cel trial update, September 2024

(25:35)

Oncolytic virus - medical animation - Imugene CHECKvacc

(2:21)

Imugene (ASX: IMU) – New Global Partnership Announced For This Leading ASX Biotech

(14:2)

Imugene expands CAR T-Cell and Oncolytic Virotherapy trials in Australia and the US

(5:25)

Imugene forges development path of immunotherapies and cancer-killing virus

(24:2)

Imugene Limited (ASX:IMU) Three Complete Responses in Azer-Cel Phase 1b Trial

(3:51)

Imugene (ASX: IMU) – The ‘Holy Grail’ Of Cancer Treatment…?! | ASX CEO Interview 🚀📈

(20:37)

Groundbreaking cancer trial: Imugene’s CF33 advances in clinical success

(16:2)

Imugene Limited (ASX: IMU) Emergence 2024: Presentation by Leslie Chong, Managing Director and CEO

(7:40)

Imugene: Serious inroads – a highly successful cancer drug trial

(3:7)

Imugene CEO And COO Speak With JustStocks Video After Promising Results In Blood Cancer Trial

(7:17)

'The Why' | Imugene, Developing Cancer Immunotherapies ASX: IMU

(4:51)

Imugene CEO hails clinical milestone for HER-Vaxx cancer immunotherapy

(6:15)

Imugene talks VAXINIA MAST trial and corporate ambition

(4:15)

Imugene featured on Behind The Scenes with Host Laurence Fishburne.

(5:15)